Showing results (181-190 of 215) with videos related to
Sort By:
Pageof 22
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.Journal of Neurovirology|May 20, 2016
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemiaSam Nightingale, Anna Maria Geretti, Apostolos Beloukas, et al.Journal of Virus Eradication|July 11, 2024
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trialJasmini Alagaratnam, Wolfgang Stöhr, Elizabeth Hamlyn, et al.The Journal of Antimicrobial Chemotherapy|February 26, 2013
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoringAlan Winston, Sophie Jose, Sara Gibbons, et al.HIV Medicine|October 18, 2023
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023Juan Ambrosioni, Laura Levi, Jasmini Alagaratnam, et al.Cytokine|May 2, 2016
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSFSam Nightingale, Benedict D Michael, Martin Fisher, et al.JAMA|July 24, 2012
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton, Ruth L Goodall, David T Dunn, et al.Journal of Virus Eradication|October 6, 2021
No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approachJasmini Alagaratnam, Wolfgang Stöhr, Jamie Toombs, et al.Pageof 22